Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tardive dyskinesia
Marketing
Neurocrine joins in on Tardive Dyskinesia Awareness Week
Neurocrine, maker of the first drug approved by the FDA to treat TD, is throwing its weight behind efforts to improve awareness of the disorder.
Andrea Park
May 6, 2024 10:52am
Neurocrine's Ingrezza nabs Huntington's nod to rival Austedo
Aug 22, 2023 9:53am
Teva's flagship drug Austedo scores new approval at the FDA
Feb 21, 2023 4:28pm
Teva's Austedo carries blockbuster expectations into 2022
Feb 9, 2022 9:49am
Teva's Austedo struggling from pandemic slowdown; All eyes on Q4
Oct 27, 2021 11:46am
Neurocrine raises a monument to mental health
Oct 8, 2021 9:40am
